

Last update: March 31, 2026

Pharmacotherapy for psoriasis: Topical corticosteroids¹⁻²⁷

Considerations:

- TCS are very effective at managing redness and itching. They are somewhat effective for managing thickness/infiltration and scaling.
- Rapid effect makes them ideal for **induction**, especially with very high- or high potency (Class 1-3). Greater potency yields greater effect.
- Possibility of tachyphylaxis and possible rebound effect with abrupt discontinuation.
- Flares:** Use once or twice daily until clear (usually 2-4 weeks).
- Maintenance/Taper:** Decrease frequency (e.g., alternate day then twice weekly) or alternate with non-steroid agents to maintain remission.
- Administration:** Apply topical corticosteroids to cover affected areas. Higher potencies may be required for thicker plaques.
- Onset to improvement:** 1-2 weeks depending on body area involvement and TCS potency.

Medication	Strength	Formulation	Scalp	Face and intertriginous areas	Trunk and arms/legs	Palms and soles	Nails	Cost (1 month)	Coverage (ODB/NHIB)
Very high potency (Class 1) (Max: 50 g/week; options for scalp, trunk, arms/legs, palms, soles, nails)									
Betamethasone dipropionate (Diprolene®, Topilene®) <i>Propylene glycol formulation ↑ penetration and effectiveness but may cause contact dermatitis.</i>	0.05%	Ointment	X	X	✓	✓	✓	\$22-56	✓
		Cream	X	X	✓	✓	✓		
		Lotion	✓	X	✓	X	X		
Clobetasol propionate (Clobex®, Dermovate®)	0.05%	Ointment	X	X	✓	✓	✓	\$22-32	✓
		Cream	✓	X	✓	✓	✓		
		Scalp application	✓	X	X	X	X		
		Shampoo	✓	X	X	X	X	\$58-102 *\$156/bottle	X
		Spray	✓	X	X	X	X	\$92-172 *\$138/bottle	
Halobetasol propionate (Bryhali®, Ultravate®)	0.05%	Ointment	X	X	✓	✓	✓	\$32-50	✓
		Cream	✓	X	✓	✓	✓		
	0.01%	Lotion	✓	X	✓	X	X	\$56-98	ODB: ✓ NIHB: X
High potency (Class 2 and 3) (Max: 100 g/week; options for scalp, trunk, arms/legs, palms, soles, nails)									
Amcinonide (Cyclocort®)	0.1%	Cream	✓	X	✓	✓	✓	\$32-50	✓
Betamethasone dipropionate (Diprosone®)	0.05%	Ointment	X	X	✓	✓	✓	\$21-31	✓
		Cream	✓	X	✓	✓	✓		
		Lotion	✓	X	✓	X	X		
Desoximetasone (Topicort®)	0.25%	Ointment	X	X	✓	✓	✓	\$50-88	X
		Cream	✓	X	✓	✓	✓		
	0.05%	Gel	✓	X	✓	✓	✓	\$43-72	
Fluocinonide (Lidex®, Lyderm®)	0.05%	Ointment	X	X	✓	✓	✓	\$27-41	✓
		Cream	✓	X	✓	✓	✓	\$24-34	
		Gel	✓	X	✓	✓	✓	\$27-42	

Medication	Strength	Formulation	Scalp	Face and intertriginous areas	Trunk and arms/legs	Palms and soles	Nails	Cost (1 month)	Coverage (ODB/NHIB)
Medium potency (Class 4 and 5) (Options for scalp, trunk, arms/legs)									
Beclomethasone dipropionate (Propaderm®)	0.025%	Cream	✓	✗	✓	✗	✗	\$39-65	✓
Betamethasone valerate (Betaderm®, Ectosone®)	0.05%	Ointment	✗	✗	✓	✗	✗	\$15-20	✓
	0.1%								
	0.05%	Cream	✓	✗	✓	✗	✗		
	0.1%								
	0.05%	Lotion	✗	✗	✓	✗	✗		
	0.1%								
0.1%	Scalp lotion	✓	✗	✗	✗	✗	\$18-32		
Clobetasone butyrate (Spectro EczemaCare®) Available without a prescription	0.05%	Cream	✓	✗	✓	✗	✗	\$30-46	ODB: ✗ NIHB: ✓
Desoximetasone (Topicort Mild®)	0.05%	Cream	✓	✗	✓	✗	✗	\$38-63	✓
Hydrocortisone valerate (HydroVal®)	0.2%	Ointment	✗	✗	✓	✗	✗	\$20-27	✓
		Cream	✓	✗	✓	✗	✗		
Mometasone furoate (Elocom®)	0.1%	Ointment	✓	✗	✓	✗	✗	\$22-32	✓
		Cream	✓	✗	✓	✗	✗	\$36-59	
		Lotion	✓	✗	✓	✗	✗	\$28-43	
Prednicarbate (emollient base) (Dermatop®)	0.1%	Cream	✓	✗	✓	✗	✗	\$111-208	✗
Triamcinolone acetonide (Aristocort R®, Aristocort C®, Triaderm®, Oracort®)	0.1%	Ointment	✓	✗	✓	✗	✗	\$21-29	✓
	0.1%	Cream	✓	✗	✓	✗	✗	\$21-29	ODB: ✗ NIHB: ✓
	0.5%							\$87-162	
	0.1%	Oral paste	✗	✗	✗	✗	✗	N/A	✓

Medication	Strength	Formulation	Scalp	Face and intertriginous areas	Trunk and arms/legs	Palms and soles	Nails	Cost (1 month)	Coverage (ODB/NHIB)
Low potency (Class 6 and 7) (Options for scalp, trunk, arms/legs, face, intertriginous areas)									
Desonide	0.05%	Ointment	✓	✓	X	X	X	\$25-38	✓
		Cream	✓	✓	X	X	X		
Fluocinolone acetonide (Derma-Smoothe/FS®, DermOtic Oil®)	0.01%	Body oil	X	✓	X	X	X	\$26-39	ODB: X NIHB: ✓
		Scalp oil	✓	X	X	X	X		
		Ear drops	X	X	X	X	X	N/A	
Hydrocortisone (Hyderm®, Cortoderm®) <i>Available without a prescription</i>	0.5%	Ointment	✓	✓	X	X	X	\$19-27	✓
	1%								
	0.5%	Cream	✓	✓	X	X	X	\$19-21	ODB: X NIHB: ✓
	1%								✓

Legend:

NIHB = Non-Insured Health Benefits; **ODB** = Ontario Drug Benefit; **TCS** = topical corticosteroid

Area specific application above denoted by '✓' and 'X' are recommendations based on potency, formulation vehicle and expert opinion. However, the potency and formulation may have additional use cases not captured in the table. Clinical judgment is still warranted in selection.

Pregnancy: Safe during pregnancy (cumulative doses < 60 g/week). There have been reports of low fetal birth weight with prolonged potent topical corticosteroid use during pregnancy.

Breastfeeding: Safe as long as away from the nipple and areola.

Cost: Several assumptions were made to derive a cost estimate. An approximation to cover a BSA of 5% (~1.25 grams per application) for a 1-month supply, using the once-daily and twice-daily doses (including a 10% markup and a \$12.99 dispensing fee).

Side effects:

Topical: Burning, stinging, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, miliaria, erythema, telangiectasia, bruising, pigment changes, lichenified dermatitis, pustulation

Systemic (can occur when used over large surface area, with prolonged use, or if combined with occlusive dressings): HPA axis suppression, adrenal insufficiency (weakness, weight loss, hypotension, and gastrointestinal distress), Cushing's syndrome, hyperglycemia, glucosuria, hypertension, immunosuppression/infection risk (rare), visual symptoms, upper respiratory tract infection, gastroenteritis (rare)

Not an exhaustive list, consult the monograph for additional considerations.

Contraindications: Hypersensitivity to corticosteroids or other ingredients in the formulation, viral skin disease (e.g., herpes simplex, varicella) or untreated infections of the skin

References

1. Bausch Health CI. LIDEX (fluocinonide cream, ointment and gel) product monograph. 2021 -03-25.
2. Organon Canada Inc. ELOCOM (mometasone furoate cream, ointment and lotion) product monograph. 2025.
3. Pendopharm. Division of Pharmascience Inc. pdp-DESONIDE (desonide cream and ointment) product monograph. Montreal (QC): Pendopharm. 2021 -03-26.
4. Taro Pharmaceuticals Inc. TARO-AMCINONIDE (amcinonide cream and ointment) product monograph. 2016 -01-15.
5. Wu M, Fischer G. Adult genital psoriasis: an updated review for clinicians. *Australas J Dermatol* 2024;65:1.
6. Nast A, Smith C, Spuls PI, Valle A, Bata-Csorgo G, Boonen Z, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris -Part 1: treatment and monitoring recommendations. *J Eur Acad Dermatol Venereol* 2020;34(11):2461–2498.
7. Shreiber AM, Friery E. Psoriasis: update on topical therapy. *Am Fam Physician* 2022;105(5):558–560.
8. Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis D. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. *J Am Acad Dermatol* 2020;82(6):1445–1486.
9. Canada V, L P. ARISTOCORT (triamcinolone acetonide) prescribing information. 2014.
10. Ribera M, Daudén E, Sahuquillo-Torralba A, Rodríguez-Fernández L, La Cueva D, Carrascosa P, et al. Expert recommendations on topical therapy for psoriasis from the Spanish Psoriasis Working Group (GPS). *Actas Dermosifiliogr* 2025;116.
11. Taro Pharmaceuticals Inc. LYDERM (fluocinonide ointment, gel, and cream) product monograph. 2023 -12-06.
12. Taro Pharmaceuticals Inc. HYDROVAL (hydrocortisone valerate cream and ointment) product monograph. 2008 -07-25.
13. Taro Pharmaceuticals Inc. DERMOVATE (clobetasol propionate cream and ointment) prescribing information. 2003 -08-06.
14. Bausch Health CI. PROPADERM (beclomethasone cream, BP) prescribing information. 2020 -12-10.
15. Hill Dermaceuticals I. Derma-Smoother/FS (fluocinolone acetonide) product monograph. 2018 -05-10.
16. Haleon Canada, Ulc. Spectro EczemaCare Medicated Cream (clobetasone cream, B.P.) product monograph. 2024 -09-05.
17. Galderma Canada I. CLOBEX SPRAY (clobetasol propionate spray) product monograph. 2022 -05-12.
18. Galderma Canada I. CLOBEX SHAMPOO (clobetasol propionate shampoo) product monograph. 2022 -05-12.
19. Bausch Health CI. ULTRAVATE (halobetasol propionate cream and ointment) product monograph. 2021 -05-12.
20. Health B, Inc C. DERMATOP OINTMENT and DERMATOP EMOLLIENT CREAM (prednicarbate ointment and prednicarbate cream) product monograph. 2022 -04-27.
21. Bausch Health CI. TOPICORT (desoximetasone cream, gel, and ointment) product monograph. 2022 -05-31.
22. Bausch Health CI. BRYHALI (halobetasol propionate lotion) product monograph. 2023 -08-14.
23. Organon Canada Inc. DIPROLENE (betamethasone dipropionate ointment) product monograph. 2021 -04-13.
24. Strober B, Ryan C, Van De Kerkhof P. Recategorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council. *J Am Acad Dermatol* 2019 -08-16;82(1):117–122.
25. Mason AR, Mason J, Cork M. Topical treatments for chronic plaque psoriasis. *Cochrane Database Syst Rev*. 2013 -03-28;2013.
26. Elmets CA, Korman NJ, Prater EF. Joint AADNPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. *J Am Acad Dermatol* 2021 -02;84(2):432–470.
27. [Expert Opinion](#).